Shares of UnitedHealth Group tumbled nearly 8% in premarket trading Tuesday following the unexpected resignation of CEO Andrew Witty and the suspension of the company’s 2025 financial outlook, according to a report by the Financial Times.
Witty, who took over the reins in 2021 after a high-profile tenure as CEO of UK pharmaceutical giant GSK, is stepping down for what the company described as “personal reasons.” His departure marks another shake-up for the U.S. healthcare giant, which is already contending with mounting operational challenges and the lingering impact of internal upheaval.
Stephen Hemsley, the company’s longtime executive chair and former CEO from 2006 to 2017, will return to the top job to steer UnitedHealth through a period of heightened uncertainty. The leadership change comes as the insurer faces surging costs tied to its Medicare Advantage plans — privately administered versions of the federal program for senior citizens.
UnitedHealth said that expenses associated with new enrollees in these plans have “remained higher than expected,” prompting a downward revision of its 2024 outlook and the scrapping of its 2025 forecast altogether.
The company is also still recovering from the shock of the tragic death of Brian Thompson, the head of its UnitedHealthcare insurance division, who was killed last year. His loss dealt a significant blow to the insurer’s leadership bench and internal stability.
The market reaction was swift and severe, with investors rattled by both the operational headwinds and the sudden executive turnover. The uncertainty around future performance — especially in the high-stakes Medicare Advantage segment — has cast doubt over UnitedHealth’s near-term trajectory.
The Financial Times notes that while UnitedHealth has long been a pillar of the U.S. health insurance industry, these recent developments may test investor confidence and strategic continuity in ways the company hasn’t experienced in years.
With Hemsley’s return, the firm is leaning on a seasoned hand to navigate this turbulent stretch. Still, analysts warn that without clear visibility on cost controls and growth in its senior care programs, UnitedHealth may face increased scrutiny from both Wall Street and Washington in the months ahead.
